NCT07489885

Brief Summary

A Study looking at the safety and efficacy of D-2570 in Participants with Plaque Psoriasis

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
75

participants targeted

Target at P50-P75 for phase_2

Timeline
18mo left

Started May 2026

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress4%
May 2026Dec 2027

First Submitted

Initial submission to the registry

March 18, 2026

Completed
6 days until next milestone

First Posted

Study publicly available on registry

March 24, 2026

Completed
1 month until next milestone

Study Start

First participant enrolled

May 1, 2026

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2027

Expected
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2027

Last Updated

March 27, 2026

Status Verified

March 1, 2026

Enrollment Period

1.3 years

First QC Date

March 18, 2026

Last Update Submit

March 23, 2026

Conditions

Psoriasis

Keywords

Moderate to Severe Plaque Psoriasis

Outcome Measures

Primary Outcomes (1)

  • Improvement in PASI-90

    Proportion of participants achieving at least a 90% improvement from baseline in Psoriasis Area and Severity Index (PASI-90) at Week 12

    Assessment completed after 12 weeks of treatment/placebo

Study Arms (3)

D-2570 low dose

ACTIVE COMPARATOR

Low dose of D-2570

Drug: D-2570 Tablet

D-2570 High Dose

ACTIVE COMPARATOR

medium dose level of D-2570

Drug: D-2570 Tablet

Placebo

PLACEBO COMPARATOR

Placebo arm

Drug: Placebo Tablets

Interventions

D-2570 TabletDRUG

Active Treatment

D-2570 High DoseD-2570 low dose
Placebo TabletsDRUG

Identical Tablet

Placebo

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Participants with a diagnosis of plaque psoriasis with no significant flares of disease activity for at least 6 months before signing the informed consent
  • Participants have moderate to severe plaque psoriasis as defined by a total body surface area (BSA) ≥10%, a Psoriasis Area and Severity Index (PASI) score ≥ 12 and a Physician's Global Assessment (PGA) score ≥ 3.
  • Within normal ranges of laboratory assessments

You may not qualify if:

  • Any comorbidities or past medical conditions as outlined in the protocol that would interfere with study assessments as deemed by the Investigator

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Psoriasis

Condition Hierarchy (Ancestors)

Skin Diseases, PapulosquamousSkin DiseasesSkin and Connective Tissue Diseases

Central Study Contacts

Kathryn Stazzone

CONTACT

3025195966kathryn.stazzone@inventisbio.com

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 18, 2026

First Posted

March 24, 2026

Study Start

May 1, 2026

Primary Completion (Estimated)

August 1, 2027

Study Completion (Estimated)

December 1, 2027

Last Updated

March 27, 2026

Record last verified: 2026-03